Clinical Trial Detail

NCT ID NCT03439462
Title ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Aadi, LLC
Indications

colorectal cancer

Therapies

Bevacizumab + Fluorouracil + Leucovorin + Nab-Rapamycin + Oxaliplatin

Age Groups: senior adult

No variant requirements are available.